Karyopharm Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Karyopharm Therapeutics sits in the top decile of US sponsors by registered trial count (#626 of 15,742 sponsors by registered trial count).
Karyopharm Therapeutics: 25 sponsored US clinical trials, 5 recruiting.
Karyopharm Therapeutics sponsors 25 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 9 completed. 4 of these trials are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Myelofibrosis, with 3 trials.
Top-decile sponsor footprint
Karyopharm Therapeutics ranks in the top decile of sponsors by registered trial count (#626 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
9 of 17 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (52.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
25 total, page 1 of 1
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
NCT05980806
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
NCT05611931
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT04442022
Selinexor and Backbone Treatments of Multiple Myeloma Patients
NCT02343042
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NCT02227251
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis
NCT04562870
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
NCT04562389
Maintenance with Selinexor/Placebo After Combination Chemotherapy in Participants with Endometrial Cancer [SIENDO]
NCT03555422
A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations
NCT04854434
Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
NCT04768881
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
NCT04421378
Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection
NCT04349098
Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma
NCT03110562
PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)
NCT02702492
Selinexor in Advanced Liposarcoma
NCT02606461
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
NCT02649790
Selinexor Treatment of Refractory Myeloma
NCT02336815
Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation
NCT02138786
Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas
NCT02213133
SHIP (Selinexor in Hormone Insensitive Prostate Cancer)
NCT02146833
Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas
NCT01986348
Selinexor (KPT-330) in Older Patients With Relapsed AML
NCT02088541
A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma
NCT01896505
Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
NCT01607892
Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
NCT01607905
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 14 |
| Phase 3 | 4 |
What is open in the Karyopharm Therapeutics pipeline
5 recruiting of 25 indexed (20% open); 9 completed (36%).
Phase mix: 4 late (III/IV) vs 21 early (I/II) (early-phase heavy).
Top condition: Myelofibrosis (3 trials), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Karyopharm Therapeutics: open-pipeline peers nationwide
Peers matched on 25 registered trials and 20% open enrollment, not the therapeutic-area sidebar.
Karyopharm Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 25 trials (± recruiting share)
- Arcus Biosciences · 25 trials · 12% recruiting
- Arcutis Biotherapeutics · 25 trials · 8% recruiting
- Ardelyx · 25 trials · 12% recruiting
- Drexel University College of Medicine · 25 trials · 0% recruiting
Sponsors near 20% open enrollment (± trial volume)
- Acera Surgical · 20% recruiting · 5 trials
- Align Technology · 20% recruiting · 5 trials
- AltruBio · 20% recruiting · 5 trials
- Alvernia University · 20% recruiting · 5 trials
Related
What to do with this Karyopharm Therapeutics page
25 registered trials is a research-attention snapshot, not an endorsement of Karyopharm Therapeutics or any single study.
- 5 of Karyopharm Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Myelofibrosis is the condition Karyopharm Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Myelofibrosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Karyopharm Therapeutics pipeline card: 25 registered trials from official public datasets.Report a data error.